PriceTargets.com logo

NASDAQ:ADIL - Adial Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.79 As of 06/21/2021 03:34 PM ET
▼ -0.13 (-4.45%)

This chart shows the closing price for ADIL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Adial Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADIL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADIL

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Adial Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.79.

This chart shows the closing price for ADIL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Adial Pharmaceuticals. This rating has held steady since May 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2019Maxim GroupSet Price TargetBuy$5.00Medium
4/12/2019Dawson JamesReiterated RatingBuyMedium
3/26/2019Maxim GroupSet Price TargetBuy$5.00Low
12/13/2018Maxim GroupReiterated RatingBuy$5.00High
11/14/2018Maxim GroupReiterated RatingBuy$5.00Low
10/30/2018Maxim GroupInitiated CoverageBuy ➝ Buy$5.00Low
10/11/2018Dawson JamesInitiated CoverageBuyHigh
10/1/2018Dawson JamesReiterated RatingBuyLow
(Data available from 6/21/2016 forward)
Adial Pharmaceuticals logo
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.
Read More

Today's Range

Now: $2.79
Low: $2.79
High: $2.86

50 Day Range

MA: $2.39
Low: $2.02
High: $2.92

52 Week Range

Now: $2.79
Low: $1.14
High: $4.00

Volume

1,236 shs

Average Volume

447,399 shs

Market Capitalization

$50.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Adial Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Adial Pharmaceuticals in the last twelve months:
View the latest analyst ratings for ADIL.

What is the current price target for Adial Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Adial Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Adial Pharmaceuticals in the next year.
View the latest price targets for ADIL.

What is the current consensus analyst rating for Adial Pharmaceuticals?

Adial Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ADIL.

What other companies compete with Adial Pharmaceuticals?

Other companies that are similar to Adial Pharmaceuticals include Aptinyx, Neptune Wellness Solutions, Savara, Medicenna Therapeutics, Decibel Therapeutics, vTv Therapeutics, Strongbridge Biopharma, Immunome, Lannett, OptiNose, VYNE Therapeutics, 180 Life Sciences, Biofrontera, 4D pharma and MediciNova.

How do I contact Adial Pharmaceuticals' investor relations team?

Adial Pharmaceuticals' physical mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company's listed phone number is 434-422-9800 and its investor relations email address is [email protected] The official website for Adial Pharmaceuticals is www.adialpharma.com.